Gattringer pointed out that the most important, most weighted variable was the NIHSS stroke score. "Patents with highest stroke severity on this scale scored 5 points — that's almost half the ...

Secondary efficacy outcomes included an NIHSS score of 2 or less at 24 hours, the change from baseline to 24 hours in the NIHSS score, a 90-day modified Rankin scale score of 0 or 1 and 0 to 2, a ...

There was no significant between-group difference for the secondary endpoint of recovering to a Rankin score of 0 or 1 (20.6% for treated patients vs 28.8% for placebo; adjusted P = .10).

Subgroup analyses were prespecified for the primary outcome according to age (≤70 or >70 years), dichotomous baseline NIHSS score (6 to 20 or >20), baseline NIHSS score (6 to 9, 10 to 20, or >20 ...

Early neurologic deterioration -- as measured by an increase of 2 or more points on the National Institutes of Health Stroke Scale (NIHSS) at 7 days -- occurred in fewer of those on DAPT (4.8% vs ...

The median time from stroke onset to randomization was 4.6 hours. The median NIHSS score was 2. The primary outcome was a return to baseline neurological functioning according to the mRS score at 90 ...

The proportion of patients with an increase in NIHSS score of 4 points or more in the first 72 hours was 4.2% among those treated with tirofiban and 13.2% among those treated with oral aspirin, a ...

The median baseline NIHSS score was 19. ... Meanwhile, the secondary endpoint of proportion of 90-day mRS score range of 0 to 2 favored the thrombectomy arm (14.6% vs 8.9%).